FAS will transfer the materials of the case on supplying “Revlimid” medicinal drug to the law enforcement bodies

The Commission of the Federal Antimonopoly Service (FAS Russia) terminated the proceedings against “SIRIUS” Ltd. (Yekaterinburg) on violating the antimonopoly law because a decision is made to transfer the case materials to the law enforcement bodies for further investigation.

The case was opened upon a complaint of “Selgen International Holdings Corporation” (US) that “SIRIUS” Ltd. violated the antimonopoly law by lawfully using an invention under No. 2177944 patent. The patent provides legal protection to a chemical substance with “Lenalidomid” International Non-Proprietary Name used to treat malignant hematological diseases.

In the Russian Federation the invention registered under No. 2177944 patent is used in a medicine with “Revlimid”trade name. The drug is included in the list of vital and essential medicinal drugs. In Russia this original (reference) drug is put into circulation upon the right-holder’s consent – “Pharmstandard” PJSC.

“SIRIUS” Ltd. won No. 0172200001916000291 electronic procurement. Following the procurement results, St Petersburg Health Care Department concluded a contract with the company for supplying the medicinal drug with “Lenalidomid” International Non-Proprietary Name under “Revlimid”trade name.

Executing the government contract, the company supplied “Revlimid”, series A2110F and A2106A, to the ordering party. According to “Pharmstandard” PJSC, however, earlier those drug series were supplied to three public health care institutions on the basis of government contracts concluded with the Ministry of Health Care of the Russian Federation.

FAS will ask the law enforcement bodies to find out how the drug used to treat malignant hematological diseases and supplied to public health care institutions, once again appeared on the market of medicinal drugs of the Russian Federation.